PRKDC and melanoma: As a result, the sensitivity to 5-FU showed the most significant positive correlation with the protein expression of PRKDC (5-FU: Spearman’s r = 0.77, p = 0.026), suggesting that melanoma patients who harbor PRKDC amplicons might be more sensitive to 5-FU treatment (Supplementary Fig. S3g).